NEW
Stock Screener with Intrinsic Value
Eli Lilly and Company (LLY)
Last Price$725.7(4.2%)
Market Cap$653.9B
WACC
7.5%
Cost of Equity
7.8%
Cost of Debt
0.4%
Debt to Equity
4.8%
Beta
1.0
Stock quality
7/10
Great
LLY WACC
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
LLY Cost of Equity
Crunching data... Almost there!
LLY vs Peer Set: Discount Rate Comparison
WACC
Cost of Equity
General
Discount rate
financials
Company name
Revenue growth
EPS growth
Net Income margin
Eli Lilly and CompanyLLY
7.5%
19.6%
(15.9%)
15.4%
Median Peer Set
6.5%
(0.6%)
3.1%
17.8%
Johnson & JohnsonJNJ
7.2%
6.5%
102.3%
41.3%
Merck & Co., Inc.MRK
6.9%
1.4%
(97.6%)
0.6%
Novartis AGNVS
6.8%
(10.0%)
124.1%
31.8%
Gilead Sciences, Inc.GILD
6.7%
(0.6%)
24.0%
20.9%
AbbVie Inc.ABBV
6.5%
(6.4%)
(58.9%)
9.0%
Amgen Inc.AMGN
5.9%
7.1%
3.1%
23.8%
Pfizer Inc.PFE
5.8%
(41.7%)
(93.2%)
3.6%
Bristol-Myers Squibb CompanyBMY
5.6%
(2.5%)
30.6%
17.8%
SanofiSNY
negative
4.1%
(33.9%)
11.7%
Explore more intrinsic value tools hub for LLY
Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Eli Lilly and Company's discount rate as of Jan 17, 2025?
As of Jan 17, 2025, Eli Lilly and Company's discount rate is 7.49%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Eli Lilly and Company's capital structure and risk profile.
What is Eli Lilly and Company's weighted average cost of capital (WACC)?
Eli Lilly and Company's WACC as of Jan 17, 2025, is 7.49%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.
What is Eli Lilly and Company's cost of equity?
Eli Lilly and Company's cost of equity is 7.8%, as of Jan 17, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.